CDK5 and fragile X-associated tremor/ataxia syndrome: Cdk5 has been proved to play a key role in many other neurological diseases, such as ALS (Bk et al., 2019), early brain injury (Ding et al., 2022), cerebral amyloidosis (Kiss et al., 2020), fragile X-associated tremor/ataxia syndrome (FXTAS; Robin et al., 2017), spinal muscular atrophy (Tejero et al., 2020), and systemic sclerosis (Wei et al., 2017).